Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 26.67B |
| Revenue (ttm) | 1.82B |
| Net Income (ttm) | -208.75M |
| Shares Out | n/a |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | 181.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,676 |
| Average Volume | 124 |
| Open | 255.80 |
| Previous Close | 259.92 |
| Day's Range | 254.14 - 262.11 |
| 52-Week Range | 143.66 - 250.15 |
| Beta | n/a |
| RSI | 55.12 |
| Earnings Date | May 1, 2025 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceutica...
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03) . The company reported quarterly sales of $594....
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Telsey Ad...
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen Inc. (NASDAQ: BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52 . The c...
Alnylam Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam reiterates 2025 guidance with projected 36% growth in TTR franchise revenues
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 11.06% on an annualized basis producing an average annual return of 19.26%. Currently, Alnylam Pharmaceuti...
Alnylam Pharmaceuticals Non-GAAP EPS of -$0.01 beats by $0.36, revenue of $594.19M beats by $9.42M
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...
Alnylam Pharmaceuticals Q1 2025 Earnings Preview
Alnylam, Halozyme among latest firms to win EU backing for drugs
EMA panel supports Alnylam & Halozyme drugs' marketing approval for rare diseases. Read more here.
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...
How Do Investors Really Feel About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's (NYSE: ALNY) short percent of float has risen 17.69% since its last report. The company recently reported that it has 2.99 million shares sold short , which is 3.06% of all ...
BofA Raises Price Target on Alnylam (ALNY) Ahead of Q1 Earnings | ALNY Stock News
BofA Raises Price Target on Alnylam (ALNY) Ahead of Q1 Earnings | ALNY Stock News
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 8.52% on an annualized basis producing an average annual return of 19.0%. Currently, Alnylam Pharmaceutica...
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Several exemptions exist among President Donald Trump ‘s broad tariffs , which were announced on Wednesday . The biopharma industry has historically been shielded from tariffs, including during Trump’...
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HEL...
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (F...
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering.